
|Videos|October 7, 2016
Scrutiny of High Drug Costs Require Specialty Pharmacy Strategy Shift
Author(s)Lauren Santye, Assistant Editor
Suzette DiMascio, CHE, CMCE, CPC, president and CEO of CSI Specialty Group, discusses how specialty pharmacies may need to alter current strategies with increasing attention on high drug costs.
Advertisement
Suzette DiMascio, CHE, CMCE, CPC, president and CEO of CSI Specialty Group, discusses how specialty pharmacies may need to alter current strategies with increasing attention on high drug costs.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Updates in Treatment of Unresectable Hepatocellular Carcinoma
2
Soaring off the Patent Cliff: Preparing for the Next Wave of Oncology Biosimilars
3
FDA Approves Depemokimab as Add-On Maintenance Treatment in Severe Asthma
4
Infliximab and Adalimumab Biosimilars Maintain Comparable Safety, Efficacy, Immunogenicity in IBD
5











































































































































































































